As of 2025-01-14, the Relative Valuation of Theravance Biopharma Inc (TBPH) is (6.48) USD. This relative valuation is based on P/E multiples. With the latest stock price at 8.78 USD, the upside of Theravance Biopharma Inc based on Relative Valuation is -173.8%.
The range of the Relative Valuation is (6.19) - (7.60) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 6.0x - 10.2x | 6.5x |
| Forward P/E multiples | 6.2x - 7.6x | 6.4x |
| Fair Price | (6.19) - (7.60) | (6.48) |
| Upside | -170.5% - -186.5% | -173.8% |
| Date | P/E |
| 2025-01-10 | -8.74 |
| 2025-01-08 | -9.01 |
| 2025-01-07 | -9.21 |
| 2025-01-06 | -9.15 |
| 2025-01-03 | -9.27 |
| 2025-01-02 | -9.24 |
| 2024-12-31 | -9.37 |
| 2024-12-30 | -9.43 |
| 2024-12-27 | -9.55 |
| 2024-12-26 | -9.81 |
| 2024-12-24 | -9.80 |
| 2024-12-23 | -9.74 |
| 2024-12-20 | -9.55 |
| 2024-12-19 | -9.68 |
| 2024-12-18 | -9.66 |
| 2024-12-17 | -9.91 |
| 2024-12-16 | -9.75 |
| 2024-12-13 | -9.83 |
| 2024-12-12 | -9.82 |
| 2024-12-11 | -9.99 |
| 2024-12-10 | -10.03 |
| 2024-12-09 | -9.94 |
| 2024-12-06 | -9.83 |
| 2024-12-05 | -9.79 |
| 2024-12-04 | -9.55 |
| 2024-12-03 | -9.79 |
| 2024-12-02 | -9.40 |
| 2024-11-29 | -9.21 |
| 2024-11-27 | -9.38 |
| 2024-11-26 | -9.20 |
| 2024-11-25 | -9.43 |
| 2024-11-22 | -9.43 |
| 2024-11-21 | -9.57 |
| 2024-11-20 | -9.92 |
| 2024-11-19 | -9.87 |
| 2024-11-18 | -9.45 |
| 2024-11-15 | -9.48 |
| 2024-11-14 | -9.53 |
| 2024-11-13 | -9.63 |
| 2024-11-12 | -8.87 |
| 2024-11-11 | -9.04 |
| 2024-11-08 | -8.90 |
| 2024-11-07 | -8.71 |
| 2024-11-06 | -8.67 |
| 2024-11-05 | -8.23 |
| 2024-11-04 | -8.17 |
| 2024-11-01 | -8.24 |
| 2024-10-31 | -8.20 |
| 2024-10-30 | -8.43 |
| 2024-10-29 | -8.61 |